Cantor Fitzgerald Weighs in on VYGR FY2024 Earnings

Voyager Therapeutics, Inc. (NASDAQ:VYGR) – Analysts at Cantor Fitzgerald issued their FY2024 earnings per share estimates for shares of Voyager Therapeutics in a note issued to investors on Monday, January 13th. Cantor Fitzgerald analyst P. Stavropoulos forecasts that the company will post earnings of ($0.98) per share for the year. Cantor Fitzgerald has a “Overweight” rating and a $5.73 price objective on the stock. The consensus estimate for Voyager Therapeutics’ current full-year earnings is ($0.89) per share.

Voyager Therapeutics (NASDAQ:VYGR) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.16) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.29. Voyager Therapeutics had a net margin of 15.80% and a return on equity of 8.33%. The company had revenue of $24.63 million for the quarter, compared to the consensus estimate of $12.63 million. During the same quarter last year, the firm posted ($0.59) earnings per share.

Several other brokerages have also commented on VYGR. Leerink Partners assumed coverage on Voyager Therapeutics in a research note on Wednesday, October 16th. They set an “outperform” rating and a $15.00 price target for the company. Leerink Partnrs raised shares of Voyager Therapeutics to a “strong-buy” rating in a research report on Wednesday, October 16th. Canaccord Genuity Group reaffirmed a “buy” rating and set a $14.00 price target on shares of Voyager Therapeutics in a research report on Thursday, November 14th. Wedbush assumed coverage on shares of Voyager Therapeutics in a research note on Friday, November 29th. They set an “outperform” rating and a $11.00 price objective for the company. Finally, HC Wainwright reissued a “buy” rating and issued a $30.00 target price on shares of Voyager Therapeutics in a research note on Thursday, November 14th. One equities research analyst has rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $15.97.

Voyager Therapeutics Trading Down 3.1 %

Shares of VYGR opened at $5.28 on Tuesday. Voyager Therapeutics has a twelve month low of $5.14 and a twelve month high of $10.66. The firm has a market capitalization of $288.43 million, a P/E ratio of 7.44 and a beta of 0.93. The stock’s fifty day simple moving average is $6.09 and its 200 day simple moving average is $6.80.

Insider Transactions at Voyager Therapeutics

In related news, COO Robin Swartz sold 6,500 shares of the company’s stock in a transaction that occurred on Monday, December 23rd. The stock was sold at an average price of $5.65, for a total transaction of $36,725.00. Following the sale, the chief operating officer now directly owns 112,328 shares of the company’s stock, valued at approximately $634,653.20. This represents a 5.47 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 4.53% of the company’s stock.

Hedge Funds Weigh In On Voyager Therapeutics

A number of hedge funds have recently added to or reduced their stakes in VYGR. Great Point Partners LLC acquired a new stake in shares of Voyager Therapeutics during the 2nd quarter worth approximately $12,668,000. Erste Asset Management GmbH acquired a new stake in Voyager Therapeutics in the third quarter worth $6,192,000. Armistice Capital LLC lifted its stake in Voyager Therapeutics by 11.3% in the second quarter. Armistice Capital LLC now owns 5,200,000 shares of the company’s stock valued at $41,132,000 after buying an additional 528,000 shares during the last quarter. American Century Companies Inc. boosted its holdings in shares of Voyager Therapeutics by 32.4% during the second quarter. American Century Companies Inc. now owns 1,019,332 shares of the company’s stock valued at $8,063,000 after acquiring an additional 249,659 shares during the period. Finally, Bank of New York Mellon Corp grew its position in shares of Voyager Therapeutics by 17.7% during the second quarter. Bank of New York Mellon Corp now owns 294,420 shares of the company’s stock worth $2,329,000 after acquiring an additional 44,289 shares during the last quarter. Institutional investors and hedge funds own 48.03% of the company’s stock.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.